Clinical Trial Update: Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating cixutumumab plus temsirolimus in metastatic prostate cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-resistant Prostate Cancer
• Prostate Adenocarcinoma
• Prostate Cancer
• Prostate Carcinoma

Drugs mentioned

• Cixutumumab (Cixutumumab)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-06-17